Kershenobich D

Language: English
References: 13
Page: 22-23
PDF size: 31.43 Kb.

Text Extraction

Treatment indications All patients with chronic hepatitis C virus (HCV) infections are considered prospects for antiviral treatment to prevent progression of liver damage to cirrhosis or hepatocarcinoma. The consensus is that such treatment must entail a combination of interferon alfa and rivabirin. Treatment is indicated for anti-HCV-positive, HCV RNA-positive patients with increased serum aminotransferase levels and for whom there is histological evidence of chronic hepatitis, provided there are no specific contraindications. The following should be taken into consideration when deciding whether to initiate treatment: age, comorbidities, extrahepatic manifestations such as cryoglobulinemia and glomerulonephritis, and quality of life. It is important to note that decisions on whether treatment should be implemented must not be based on the way in which the CHV was acquired or the presence or absence of symptoms. Whether HCV genotypes or HCV RNA levels are valid indicators for treatment is the subject of debate.

REFERENCES

1. Sherman M, Bain V, Villeneuve JP, Myers RP, et al. The management of chronic viral hepatitis: a Canadian consensus conference 2004. Can J Gastroenterol 2004; 18: 715-28.

2. Proceedings of the Consensus Conference on Hepatitis C. April 21–22, 2004. Edinburgh, United Kingdom. J Viral Hepat 2004; 11(Suppl.1): 1-39.

3. Camma C, Licata A, Cabibbo G, Latteri F, Craxi A. Treatment of hepatitis C: critical appraisal of the evidence. Expert Opin Pharmacother 2005; 6: 399-408.

4. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, Management, and Treatment of Hepatitis C. Hepatology 2004; 39: 1147-71.

5. Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat 2005; 12: 223-35.

6. Lo Re V 3rd, Kostman JR. Management of chronic hepatitis C. Postgrad Med J 2005; 81: 376-82.

7. Wang P, Yi Q, Scully L, Heathcote J, Krahn M. Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists. Can J Gastroenterol 2003; 17: 183-6.

8. Soriano V, Miro JM, Garcia-Samaniego J, et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations J Viral Hepat 2004; 11: 2-17.

9. Martin P, Fabrizi F. Treatment of chronic hepatitis C infection in patients with renal failure. Clin Gastroenterol Hepatol 2005; 3: S113-7.

10. Wiesner RH, Sorrell M, Villamil F. International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-9.

11. Delgado-Borrego A, Jonas MM. Treatment Options for Hepatitis C Infection in Children. Curr Treat Options Gastroenterol 2004; 7: 373-9.

12. Delwaide J, El Saqouda R, Gerard C, et al. Hepatitis C infection: eligibility for antiviral therapies. Eur J Gastroenterol Hepatol 2005; 17: 1185-9.

13. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. Veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100: 1772-9.